PERa平台:基于注册登记开展多中心实用随机试验评估放射肿瘤学创新
本研究评估PERa平台在放射肿瘤学中开展实用型注册登记随机对照试验(rRCT)的实施性能。2018至2023年间,注册登记纳入来自5家机构的1415例患者,93%同意再联系参与试验,97%同意作为对照;共启动7项嵌入式rRCT,477例(三分之一)被随机分组。仅记录2例研究臂不依从事件;ePRO同意率97%,但仅第一阶段同意者完成率53%,第二阶段同意者完成率62%。结论认为该平台接受度高,可高效嵌入常规放疗实践开展rRCT。
要点
- PERa平台在5家机构注册1415例放疗患者,支持实用型注册登记随机试验。
- 93%同意再联系参与临床试验,97%同意作为对照,接受度高。
- 启动7项嵌入式rRCT,477例被随机分组,仅2例研究臂不依从事件。
核心结论
- PERa平台在放射肿瘤学常规实践中开展rRCT获得高接受度,实施效率良好。
研究设计与样本
- 实施性研究,评估PERa平台(前瞻性标准放疗患者注册登记+实用型注册登记随机试验+分阶段知情同意)的实施性能。
- 2018年1月1日至2023年12月31日,5家参与机构共注册1415例参与者。
主要发现
- 第一阶段知情同意时,93%同意再联系参与临床试验,97%同意作为对照。
- 共启动7项嵌入式rRCT,三分之一参与者(n=477)被随机分组。
- 仅记录2例研究臂不依从事件。
- 97%受试者同意ePRO,但仅第一阶段同意者完成率53%,第二阶段同意者完成率62%。
临床怎么用
- 可在常规放疗实践中嵌入注册登记驱动的实用型随机试验,提高证据生成效率。
- 分阶段知情同意可支持患者再联系和作为对照的广泛接受。
局限性
- ePRO完成率在仅第一阶段同意者中仅53%,在第二阶段同意者中为62%,仍需改善。
- 未来需自动化与EMR数据湖的协调以提升证据生成质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiotherapy has achieved substantial progress often attributed to accelerated technological innovation over decades. However, randomized controlled trials (RCTs) are costly, difficult to fund and to conduct, such that the generation of quality evidence is outpaced by changes in practice. We sought to evaluate the implementation performance of a platform approach to the conduct of pragmatic RCTs in radiation oncology. METHODS: We implemented PERa, a platform consisting of a prospective registry of patients receiving standard-of-care radiation therapy, designed to support pragmatic registry-based RCT (rRCT) methods and staged informed consent. Implementation performance metrics included rate of registry enrollment, acceptability of re-contact and/or serving as controls for interventional trials, activation and recruitment of embedded comparative effectiveness rRCTs, compliance to study arms, and completeness of ePRO data acquired at scale. RESULTS: Between January 1, 2018 and December 31, 2023, the registry accrued 1415 participants across 5 participating institutions. At time of stage 1 consent, 93% agreed to re-contact for participation in a clinical trial, and 97% consented to serve as control. Seven embedded rRCTs were activated, and one third of participants (n = 477) were randomized. Only two study arm non-compliance events were recorded. Although 97% of subjects consented to ePROs, completion rate was only 53% in those with stage 1 only consent, rising to 62% in those subjects also consented at a second stage to a companion rRCT. CONCLUSION: The PERa platform is met with high acceptance demonstrating efficient conduct of rRCTs embedded in routine radiation oncology practice. Future work to improve ePRO completions and automate harmonization with EMR data lakes have the potential to improve the quality of evidence generation and support learning health systems. TRIAL REGISTRATION: NCT03378856: Registered on December 12, 2017. NCT04100174: Registered on September 20, 2019. NCT04178174: Registered on November 17, 2019. NCT05457699: Registered on July 04, 2022. NCT04405401: Registered on May 24, 2020. NCT04901234: Registered on May 17, 2021. NCT05317026: Registered on March 08, 2022.
引用
- Giguère P, Bahig H, Westra S, et al. Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation. Trials. 2026. PMID: 42032732. doi:10.1186/s13063-026-09709-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。